• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Ethics of Conducting Clinical Trials With Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Is Placebo Assignment Justified in Patients With Comorbid Diabetes Mellitus and Heart Failure?

作者信息

Butler Javed, Anker Stefan D

机构信息

From Division of Cardiovascular Medicine, Stony Brook University, New York (J.B.); Department of Cardiology and Pneumology and German Center for Cardiovascular Research, University Medicine Göttingen, Germany (S.D.A.); and Division of Cardiology and Metabolism-Heart Failure, Cachexia, and Sarcopenia, Department of Cardiology Campus CVK, Berlin-Brandenburg Center for Regenerative Therapies, Charité University Medicine, Germany (S.D.A.).

出版信息

Circulation. 2017 Oct 17;136(16):1459-1461. doi: 10.1161/CIRCULATIONAHA.117.029284.

DOI:10.1161/CIRCULATIONAHA.117.029284
PMID:29038205
Abstract
摘要

相似文献

1
The Ethics of Conducting Clinical Trials With Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Is Placebo Assignment Justified in Patients With Comorbid Diabetes Mellitus and Heart Failure?使用钠-葡萄糖协同转运蛋白2抑制剂进行心力衰竭临床试验的伦理问题：对于合并糖尿病和心力衰竭的患者，给予安慰剂是否合理？
Circulation. 2017 Oct 17;136(16):1459-1461. doi: 10.1161/CIRCULATIONAHA.117.029284.
2
Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.心力衰竭风险分层与钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病患者中的疗效。
Circulation. 2019 Nov 5;140(19):1569-1577. doi: 10.1161/CIRCULATIONAHA.119.042685. Epub 2019 Aug 31.
3
Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality.恩格列净与急性心力衰竭后再住院及死亡风险降低相关。
Circulation. 2019 Mar 12;139(11):1458-1460. doi: 10.1161/CIRCULATIONAHA.118.038339.
4
Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus.卡格列净对2型糖尿病患者射血分数保留和降低的心衰结局的影响。
Circulation. 2019 May 28;139(22):2591-2593. doi: 10.1161/CIRCULATIONAHA.119.040057. Epub 2019 Mar 17.
5
Treating Heart Failure With Antihyperglycemic Medications: Is Now the Right Time?使用抗高血糖药物治疗心力衰竭：现在是合适的时机吗？
Circulation. 2019 May 21;139(21):2383-2385. doi: 10.1161/CIRCULATIONAHA.119.038854.
6
Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂在伴或不伴 2 型糖尿病的急性心力衰竭患者中的疗效和安全性：系统评价和荟萃分析。
Cardiovasc Diabetol. 2022 Feb 5;21(1):20. doi: 10.1186/s12933-022-01455-2.
7
SCORED and SOLOIST: the next scores for SGLT2 inhibitors.SCORED和SOLOIST：SGLT2抑制剂的下一批试验结果
Cardiovasc Res. 2021 Mar 21;117(4):e49-e51. doi: 10.1093/cvr/cvaa355.
8
Practical Considerations for the Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure.心力衰竭中使用钠-葡萄糖协同转运蛋白2抑制剂的实际考量
Circ Heart Fail. 2020 Feb;13(2):e006623. doi: 10.1161/CIRCHEARTFAILURE.119.006623. Epub 2020 Feb 14.
9
Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist.钠葡萄糖协同转运蛋白2抑制剂对心血管结局的类效应：对心血管疾病专科医生的启示
Circulation. 2018 Mar 20;137(12):1218-1220. doi: 10.1161/CIRCULATIONAHA.117.030117.
10
Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists: With Great Power Comes Great Responsibility.心脏病专家使用钠-葡萄糖协同转运蛋白2抑制剂：能力越大，责任越大。
Circulation. 2016 Dec 13;134(24):1915-1917. doi: 10.1161/CIRCULATIONAHA.116.024764.

引用本文的文献

1
Empagliflozin prevents neointima formation by impairing smooth muscle cell proliferation and accelerating endothelial regeneration.恩格列净通过抑制平滑肌细胞增殖和加速内皮再生来预防新生内膜形成。
Front Cardiovasc Med. 2022 Aug 9;9:956041. doi: 10.3389/fcvm.2022.956041. eCollection 2022.
2
Totality of evidence in trials of sodium-glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice.射血分数降低的心力衰竭患者中钠-葡萄糖协同转运蛋白2抑制剂的试验证据汇总：对临床实践的启示
Eur Heart J. 2020 Sep 21;41(36):3398-3401. doi: 10.1093/eurheartj/ehaa731.
3
Empagliflozin, calcium, and SGLT1/2 receptor affinity: another piece of the puzzle.
恩格列净、钙与SGLT1/2受体亲和力：谜题的又一片拼图。
ESC Heart Fail. 2018 Aug;5(4):549-551. doi: 10.1002/ehf2.12345. Epub 2018 Jul 19.
4
Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics.恩格列净对心肺适应性的影响及袢利尿剂的显著相互作用。
Diabetes Obes Metab. 2018 Aug;20(8):2014-2018. doi: 10.1111/dom.13309. Epub 2018 Apr 23.
5
Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes.2 型糖尿病患者心血管结局试验中的心力衰竭患病率和发生率。
J Am Coll Cardiol. 2018 Mar 27;71(12):1379-1390. doi: 10.1016/j.jacc.2018.01.047. Epub 2018 Mar 10.
6
Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes.心力衰竭对 2 型糖尿病抗高血糖药物的考虑。
Circ Res. 2016 May 27;118(11):1830-43. doi: 10.1161/CIRCRESAHA.116.306924.